Enhancement of CO₂-Induced Anxiety in Healthy Volunteers With the Serotonin Antagonist Metergoline

Fourteen healthy volunteers (six at the National Institute of Mental Health [NIMH], Bethesda, Md., and eight at the Soroka Medical Center, Beer-sheba, Israel) underwent psychiatric screening with the overview section of the Structured Clinical Interview for DSM-III-R (9) and a standard medical interview, examination, and laboratory tests to exclude medical illness, drug or medication use, and pregnancy. During the course of the study, an additional inclusion criterion was imposed, to be described later. After complete description of the study to the subjects, including demonstration of the equipment, written informed consent was obtained.

The study used a crossover design; each subject received a capsule containing metergoline (4 mg) once and placebo once; previous experience (7, 10) suggested that this dose was sufficient to exert an effect. Inhalations were separated by at least 1 week; the order of drug and placebo administration was randomized and double-blind.

On test days, 90 minutes were allowed after administration of the capsule for habituation to the setting and for the drug to take effect, as indicated by previous assessments of physiological and neuroendocrine measures (7, 10). Then two vital capacity inhalations of compressed room air (once) and of 35% CO₂ (once) were administered, separated by 20 minutes. The order of gas inhalation was random and single-blind.

Assessments with the anxiety subscale of the NIMH self-rating scale of physical and mental symptoms (11) were performed 30 minutes before the first inhalation and immediately before and after each inhalation.

The first nine subjects who satisfied the inclusion and exclusion criteria were included without regard to their potential responses to CO₂. However, after assessment of nine subjects, we observed that only two of them (22%) had anxiogenic responses to CO₂ (defined as an increase of 2 or more points on their anxiety subscale scores). We considered that metergoline might enhance or attenuate CO₂-­induced anxiety; however, seven of these nine subjects could not have shown any attenuation of anxiety because they had little or none after CO₂ inhalation. Therefore, we selected additional subjects likely to show anxiety responses to CO₂. Subsequent potential subjects who had completed screening procedures identical to those employed with the first nine subjects received a single vital capacity inhalation of 35% CO₂ while being shown the experimental equipment; those with anxiety responses were included for further study. Fifty potential subjects underwent this screening, and five (10%) were selected.

Analysis employed repeated measures analysis of variance (ANOVA), with the NIMH self-rating anxiety subscale score as the repeated measure; drug (placebo or metergoline), gas (air or CO₂) and time relative to inhalation (before or after) as within-subjects factors; and the following between-groups factors, as appropriate: order of drug administration, site (Bethesda or Beer-sheba), selection procedure (whether screened for CO₂ response during selection or not), and responder status (response to CO₂ alone during the placebo inhalation or not). Eight subjects received placebo first, and six subjects received metergoline first.

The order of administration of the medication and placebo had no effect. The site had no effect on scores on the NIMH self-rating anxiety subscale; however, because it did affect other outcome measures (reported elsewhere), we performed this analysis with the site as a between-group factor. There were no time or drug effects during the 90-minute habituation phases. The physician (I.Z.B.-Z., G.M., or J.B.) administering the procedure guessed the order of drug and placebo administration incorrectly for five out of 11 subjects for whom this information was available.

The drug, gas, and time three-way interaction was statistically significant (Table 1). The Bonferroni t type I 5% post hoc test indicated that the only statistically significant difference within this interaction occurred after metergoline administration and between anxiety readings before and after CO₂ inhalation. The difference was 5.1 anxiety units, with the elevated reading occurring after inhalation (Table 1). Anxiety readings after placebo administration and after CO₂ inhalation were also higher than readings ­before CO₂ inhalation, but with a statistically insignificant difference of only 2.2 anxiety units. All differences between before and after air inhalations, with metergoline and placebo, were less than 0.5 anxiety units and statistically insignificant.

Metergoline enhanced CO₂-induced increases in NIMH self-rating anxiety subscale scores in two out of five subjects who responded to CO₂ alone and also provoked anxiety responses to CO₂ in six out of nine subjects who did not respond to CO₂ alone. The absence of effects during the 90 minutes between ingestion of the capsules and the first inhalation suggests that the metergoline dose was small enough to maintain the blind; this is further supported by the failure of physicians to guess the correct order of drug and placebo administration in approximately half of the cases. Therefore, we hypothesize that 5-HT may act to inhibit CO₂-induced anxiety and that this inhibition was reduced by metergoline. This is consistent with the finding that the lowering of 5-HT activity by tryptophan depletion increases ventilation, which typically parallels increases in anxiety in patients with panic disorder during CO₂ inhalation (5) and also increases some anxiety measures in healthy volunteers during CO₂ inhalation (6).

Further study with 5-HT agonists and antagonists is required to elucidate the role of 5-HT in CO₂-induced anxiety.

Received March 27, 1998; revisions received Nov. 5, 1998, and Feb. 2, 1999; accepted April 12, 1999. From the Division of Psychiatry, Soroka Medical Center; Ben Gurion University of the Negev, Beer-sheba, Israel; and the Laboratory of Clinical Science, NIMH, Bethesda, Md. Address reprint requests to Dr. Benjamin, Division of Psychiatry, Soroka Medical Center, P.O. Box 151, Beer-sheba 84101, Israel; [email protected] (e-mail)